enkephalin-leu--ala(2)-arg(6)- and Coronary-Disease

The aim of this study was to evaluate the effect of dalargin on the state of lipid peroxidation (LPO) and antioxidant system in patients with coronary heart disease (CHD) and on the background of metabolic syndrome (MS) in a group of 123 patients with stable coronary artery disease and MS (mean age 56.7 ± 5.1 years). For this purpose, the blood redox potential (EP), total antioxidant activity (TAA), level of oxidized low density lipoproteins (LDL), and activity of superoxide dismutase (SOD) were compared between the group receiving a standard medical therapy (ST) for coronary heart disease (group 1, n = 63) and that with supplementary dalargin administration (ST + D) in a dose of 1 mg intranasally twice a day for 10 days (group 2, n = 60), using the same dose for 10 days in the next two months (total 3 courses over 3 months). It was found that patients with CHD + MS upon 3-month ST showed no statistically significant changes in parameters characterizing the oxidative potential of blood (EP) and antioxidant protection of blood (oxidized LDL level, SOD activity). The inclusion of dalargin into therapy (ST + D) led to a significant decrease in the oxidative stress parameters (blood EP by 10.5%, oxidized LDL level by 14%, p < 0.001) and increase in the blood antioxidant properties (SOD activity by 36.1%, TAA by 25.3%, p < 0.001).

Topics: Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Coronary Disease; Enkephalin, Leucine-2-Alanine; Female; Humans; Lipid Peroxidation; Lipoproteins, LDL; Male; Metabolic Syndrome; Middle Aged

In cat experiments, the effects of dalargin were examined on blood pressure in the animals with its various baseline levels and on the development of ischemic arrhythmias. Dalargin was demonstrated to produce a modulating effect on blood pressure and to reduce the incidence of ventricular fibrillation in myocardial ischemia.

Topics: Animals; Blood Pressure; Cats; Coronary Disease; Coronary Vessels; Disease Models, Animal; Enkephalin, Leucine-2-Alanine; Female; Male; Vasodilator Agents

Topics: Adult; Coronary Disease; Enkephalin, Leucine; Enkephalin, Leucine-2-Alanine; Extremities; Humans; Ischemia; Male; Microcirculation; Middle Aged; Sympatholytics

The work presents the data on the immunostimulating properties of neuropeptides. As revealed in this study, the leu-enkephalin level in blood sera (taken from 55 patients) inversely correlates with the intensity of the proliferative response of lymphocytes to phytohemagglutinin. In in vitro systems dalargin promotes the increase or decrease of the proliferative response of lymphocytes to phytohemagglutinin, depending on the proliferative activity of cells in response to this mitogen, and also leads to an increase in the number of rosette-forming cells. Leu-enkephalin in doses of 100, 10, 1, 0.1 micrograms/ml and dalargin in a dose of 0.1 microgram/ml inhibit the migration of leukocytes.

Topics: Adjuvants, Immunologic; Cell Migration Inhibition; Cells, Cultured; Coronary Disease; Enkephalin, Leucine; Enkephalin, Leucine-2-Alanine; Humans; Lymphocytes; Neuropeptides; Rosette Formation

It has been shown in experiments on albino rats that acute myocardial ischemia (AMI) produces a noticeable increase in excretion of adrenaline, noradrenaline, DOPA and dopamine with urine. Intraperitoneal injection of leu-enkephalin analogs (D-Ala2-Leu5-Arg6 and D-Ala2-D-Leu5-D-Arg6) to rats with AMI was accompanied by a noticeable prevention of activation of the sympathoadrenal system.

Topics: Adrenal Glands; Animals; Catecholamines; Coronary Disease; Enkephalin, Leucine; Enkephalin, Leucine-2-Alanine; Enkephalins; Male; Rats; Sympathetic Nervous System; Time Factors

It has been demonstrated in experiments on rats that acute myocardial ischemia gives rise to a decrease in diuresis, elevation of antidiuretic activity of blood plasma and the blood concentration of immunoreactive aldosterone. Intraperitoneal injection of a synthetic enkephalin analog D-ala2-leu5-arg6-enkephalin in a dose of 1.25 nmol/kg bw resulted in partial normalization of diuresis, reduction in antidiuretic activity of blood plasma and blood aldosterone level to the control values. Naloxone eliminated the effects described. It is concluded that enkephalins have an inhibitory action on aldosterone and vasopressin secretion, with this action being mediated via opiate receptors.

Topics: Aldosterone; Animals; Coronary Disease; Diuresis; Enkephalin, Leucine; Enkephalin, Leucine-2-Alanine; Male; Naloxone; Rats; Vasopressins

Topics: Adult; Aged; Blood Pressure; Coronary Disease; Dose-Response Relationship, Drug; Drug Evaluation; Enkephalin, Leucine; Enkephalin, Leucine-2-Alanine; Heart Rate; Hemodynamics; Humans; Middle Aged; Myocardial Contraction; Stroke Volume